← Back to Clinical Trials
Recruiting NCT04320199

NCT04320199 Effect of Fermented Protaetia Brevitarsis Seulensis Powder on Alcohol-induced Liver Disease

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04320199
Status Recruiting
Phase
Sponsor Pusan National University Yangsan Hospital
Condition Alcoholic Liver Disease
Study Type INTERVENTIONAL
Enrollment 30 participants
Start Date 2020-01-01
Primary Completion 2025-12-30

Eligibility & Interventions

Sex All sexes
Min Age 19 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Fermented Protaetia brevitarsis seulensis powder groupPlacebo group

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 30 participants in total. It began in 2020-01-01 with a primary completion date of 2025-12-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The investigators conduct a randomized, double-blind, placebo-controlled study to investigate the effects of Fermented Protaetia brevitarsis seulensis powder on Alcohol-induced Liver Disease in adults for 8 weeks.

Eligibility Criteria

Inclusion Criteria: * Gamma-glutamyl transferase ranging from upper limit of reference to four times of upper limit Exclusion Criteria: * Abnormal liver or renal function (i.e., serum aminotransferase activity \> 3 times of upper limit of reference range and serum creatinine concentrations \> 1.2 mg/dL) * Diabetes (diagnosed clinically or fasting glucose level \> 126 mg/dL) * History of viral hepatitis or cancer * Uncontrolled hypertension * History of serious cardiac disease such as angina or myocardial infarction * History of gastrectomy * History of medication for psychiatric disease * Administration of oriental medicine including herbs within the past 4 weeks

Contact & Investigator

Central Contact

Sang Yeoup Lee, Professor

✉ saylee@pnu.edu

📞 360-2860

Principal Investigator

Sang Yeoup Lee, Professor

PRINCIPAL INVESTIGATOR

Pusan National University Yangsan Hospital

Frequently Asked Questions

Who can join the NCT04320199 clinical trial?

This trial is open to participants of all sexes, aged 19 Years or older, studying Alcoholic Liver Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04320199 currently recruiting?

Yes, NCT04320199 is actively recruiting participants. Contact the research team at saylee@pnu.edu for enrollment information.

Where is the NCT04320199 trial being conducted?

This trial is being conducted at Pusan, South Korea.

Who is sponsoring the NCT04320199 clinical trial?

NCT04320199 is sponsored by Pusan National University Yangsan Hospital. The principal investigator is Sang Yeoup Lee, Professor at Pusan National University Yangsan Hospital. The trial plans to enroll 30 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology